Low Dissolved Oxygen Favors Biological Phosphorus Removal, and Oxygen Inhibition of PAOs Is an Important Part of the Story
Water Environment Research · 2026-11 · 98 (11)
DOI: 10.1002/wer.70664 ↗Kurz gefasst
Fachartikel in der Zeitschrift Water Environment Research, online erschienen am 16.11.2026. Verfasst von Lilian McIntosh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Civil and Environmental Engineering, Virginia Polytechnic and State University, Blacksburg, Virginia, USA. Hauptthemen laut MEDLINE: Oxygen, Phosphorus, Polyphosphates. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Hampton Roads Sanitation District, U.S. Department of Energy's Office of Energy Efficiency and Renewable Energy (EERE), Office of Energy Efficiency and Renewable Energy.
Abstract (Originalsprache)
Conventional enhanced biological phosphorus removal (EBPR) design assumes dissolved oxygen (DO) concentrations between 2 and 4 mg/L are required to support reliable phosphorus removal, despite limited mechanistic evidence establishing the DO requirements of polyphosphate‐accumulating organisms (PAOs). This study evaluated long‐term EBPR performance, PAO oxygen kinetics, and predicted functional genes under high and low DO conditions. EBPR performance remained stable and improved at low DO, with median effluent orthophosphate concentrations at 0.2 mg DO/L 40% lower and less variable than at 2.0 mg DO/L. Batch testing revealed extremely low PAO oxygen half‐saturation coefficients (K DO < 0.1 mg/L) and maximum phosphorus uptake rates at low DO, whereas elevated DO hindered phosphorus uptake. This inhibitory behavior was described using the Andrews model, indicating that high concentrations of DO can suppress PAO activity. Exploratory functional prediction from 16S rRNA gene data indicated differences in predicted stress‐response and polyphosphate‐related gene content between DO conditions, which identify candidate genes for future gene expression studies. These findings challenge conventional design guidance and motivate direct investigation of PAO oxygen inhibition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Civil and Environmental Engineering, Virginia Polytechnic and State University, Blacksburg, Virginia, USA.
- Hampton Roads Sanitation District, Virginia Beach, Virginia, USA.
- Department of Civil, Environmental, and Architectural Engineering, University of Kansas, Lawrence, Kansas, USA.
- GFT Infrastructure, Virginia Beach, Virginia, USA.
- Hazen and Sawyer, New York, New York, USA.
- Black & Veatch, Charleston, South Carolina, USA.
ORCID-Profile: Lilian McIntosh, Dev Hiripitiyage, Kester McCullough, Riley Doyle, Belinda Sturm, Charles Bott
Förderung
- Hampton Roads Sanitation District
- U.S. Department of Energy's Office of Energy Efficiency and Renewable Energy (EERE)
- Office of Energy Efficiency and Renewable Energy
Zitieren
APA
McIntosh, L., Hiripitiyage, D., McGehee, H., Dawson, W., Bradshaw, H., McCullough, K., Doyle, R., Sturm, B., & Bott, C. (2026). Low Dissolved Oxygen Favors Biological Phosphorus Removal, and Oxygen Inhibition of PAOs Is an Important Part of the Story. Water Environment Research, 98(11). https://doi.org/10.1002/wer.70664
Vancouver
McIntosh L, Hiripitiyage D, McGehee H, Dawson W, Bradshaw H, McCullough K, et al. Low Dissolved Oxygen Favors Biological Phosphorus Removal, and Oxygen Inhibition of PAOs Is an Important Part of the Story. Water Environment Research. 2026;98(11). doi:10.1002/wer.70664
BibTeX
@article{McIntosh2026,
author = {McIntosh, Lilian and Hiripitiyage, Dev and McGehee, Haley and Dawson, William and Bradshaw, Hailey and McCullough, Kester and Doyle, Riley and Sturm, Belinda and Bott, Charles},
title = {Low Dissolved Oxygen Favors Biological Phosphorus Removal, and Oxygen Inhibition of PAOs Is an Important Part of the Story},
journal = {Water Environment Research},
year = {2026},
volume = {98},
number = {11},
doi = {10.1002/wer.70664}
}
EUVIMED